Cargando…
Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Diabetes Association
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920795/ https://www.ncbi.nlm.nih.gov/pubmed/23882041 http://dx.doi.org/10.2337/dcS13-2031 |
| _version_ | 1782303228965158912 |
|---|---|
| author | Schernthaner, Guntram Currie, Craig J. Schernthaner, Gerit-Holger |
| author_facet | Schernthaner, Guntram Currie, Craig J. Schernthaner, Gerit-Holger |
| author_sort | Schernthaner, Guntram |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3920795 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | American Diabetes Association |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-39207952014-08-01 Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013 Schernthaner, Guntram Currie, Craig J. Schernthaner, Gerit-Holger Diabetes Care Diabetes Therapy American Diabetes Association 2013-08 2013-07-17 /pmc/articles/PMC3920795/ /pubmed/23882041 http://dx.doi.org/10.2337/dcS13-2031 Text en © 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details. |
| spellingShingle | Diabetes Therapy Schernthaner, Guntram Currie, Craig J. Schernthaner, Gerit-Holger Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013 |
| title | Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013 |
| title_full | Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013 |
| title_fullStr | Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013 |
| title_full_unstemmed | Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013 |
| title_short | Do We Still Need Pioglitazone for the Treatment of Type 2 Diabetes? A risk-benefit critique in 2013 |
| title_sort | do we still need pioglitazone for the treatment of type 2 diabetes? a risk-benefit critique in 2013 |
| topic | Diabetes Therapy |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3920795/ https://www.ncbi.nlm.nih.gov/pubmed/23882041 http://dx.doi.org/10.2337/dcS13-2031 |
| work_keys_str_mv | AT schernthanerguntram dowestillneedpioglitazoneforthetreatmentoftype2diabetesariskbenefitcritiquein2013 AT curriecraigj dowestillneedpioglitazoneforthetreatmentoftype2diabetesariskbenefitcritiquein2013 AT schernthanergeritholger dowestillneedpioglitazoneforthetreatmentoftype2diabetesariskbenefitcritiquein2013 |